✦ LIBER ✦

Prognostic factors for survival of stage IB upper lobe non-small cell lung cancer patients: A retrospective study in Shanghai, China

✍ Scribed by Wen-li Wang; Yang Shen-tu; Zhi-qiang Wang

Publisher: Chinese Anti-Cancer Association
Year: 2011
Tongue: English
Weight: 500 KB
Volume: 23
Category: Article
ISSN: 1000-9604
DOI: 10.1007/s11670-011-0265-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors in patients with rese

Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group

✍ Mitchell H. Gail; Robert T. Eagan; Ronald Feld; Robert Ginsberg; Brian Goodell; 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 964 KB

Preoperative total serum cholesterol as

Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer

✍ Mihael Sok; Janez Ravnik; Maja Ravnik 📂 Article 📅 2009 🏛 Springer Vienna 🌐 English ⚖ 191 KB

Overexpression of eIF5A-2 is an adverse

Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non–small cell lung cancer patients

✍ Li-Ru He; Hong-Yun Zhao; Bin-Kui Li; Yan-Hui Liu; Meng-Zhong Liu; Xin-Yuan Guan; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 624 KB

## Abstract We have previously isolated an oncogene __EIF5A2__ (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected f

Prognostic factors for survival of stage

Prognostic factors for survival of stage I nonsmall cell lung cancer patients : A population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003

✍ S.-H. Ignatius Ou; Jason A. Zell; Argyrios Ziogas; Hoda Anton-Culver 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## BACKGROUND. Platinum‐based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC). Using data from the California Cancer Registry (CCR), we explored factors that had detrimental effects